ES2974423T3 - Uso de cladribina para el tratamiento de enfermedades neuromusculares autoinmunes - Google Patents

Uso de cladribina para el tratamiento de enfermedades neuromusculares autoinmunes Download PDF

Info

Publication number
ES2974423T3
ES2974423T3 ES18739593T ES18739593T ES2974423T3 ES 2974423 T3 ES2974423 T3 ES 2974423T3 ES 18739593 T ES18739593 T ES 18739593T ES 18739593 T ES18739593 T ES 18739593T ES 2974423 T3 ES2974423 T3 ES 2974423T3
Authority
ES
Spain
Prior art keywords
cladribine
composition
treatment
dose
administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES18739593T
Other languages
English (en)
Spanish (es)
Inventor
Konrad Rejdak
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chord Therapeutics SA
Original Assignee
Chord Therapeutics SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chord Therapeutics SA filed Critical Chord Therapeutics SA
Application granted granted Critical
Publication of ES2974423T3 publication Critical patent/ES2974423T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
ES18739593T 2017-07-21 2018-06-28 Uso de cladribina para el tratamiento de enfermedades neuromusculares autoinmunes Active ES2974423T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB1711800.1A GB2564717A (en) 2017-07-21 2017-07-21 Use of cladribine for treating autoimmune neuromuscular disease
PCT/GB2018/051801 WO2019016505A1 (en) 2017-07-21 2018-06-28 USE OF CLADRIBINE FOR THE TREATMENT OF AUTOIMMUNE NEUROMUSCULAR DISEASE

Publications (1)

Publication Number Publication Date
ES2974423T3 true ES2974423T3 (es) 2024-06-27

Family

ID=59771723

Family Applications (1)

Application Number Title Priority Date Filing Date
ES18739593T Active ES2974423T3 (es) 2017-07-21 2018-06-28 Uso de cladribina para el tratamiento de enfermedades neuromusculares autoinmunes

Country Status (16)

Country Link
US (2) US12171775B2 (OSRAM)
EP (2) EP3654989B1 (OSRAM)
JP (1) JP7186214B2 (OSRAM)
CA (1) CA3095893A1 (OSRAM)
DK (1) DK3654989T3 (OSRAM)
ES (1) ES2974423T3 (OSRAM)
FI (1) FI3654989T3 (OSRAM)
GB (1) GB2564717A (OSRAM)
HR (1) HRP20240282T1 (OSRAM)
HU (1) HUE066238T2 (OSRAM)
LT (1) LT3654989T (OSRAM)
PL (1) PL3654989T3 (OSRAM)
PT (1) PT3654989T (OSRAM)
RS (1) RS65246B1 (OSRAM)
SI (1) SI3654989T1 (OSRAM)
WO (1) WO2019016505A1 (OSRAM)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2601786A (en) 2020-12-10 2022-06-15 Chord Therapeutics S A R L Use of cladribine for treating immune brain disease
WO2025125527A1 (en) 2023-12-14 2025-06-19 Ares Trading S.A. Cladribine regimen for treating myasthenia gravis

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1269659A (en) 1984-08-06 1990-05-29 Brigham Young University Method for the production of 2'-deoxyadenosine compounds
US5310732A (en) 1986-02-03 1994-05-10 The Scripps Research Institute 2-halo-2'-deoxyadenosines in the treatment of rheumatoid arthritis
US5208327A (en) 1991-12-18 1993-05-04 Ortho Pharmaceutical Corporation Intermediates useful in a synthesis of 2-chloro-2'-deoxyadenosine
WO2001007054A1 (en) * 1999-07-22 2001-02-01 Supergen, Inc. Methods for treating autoimmune diseases
US20040162263A1 (en) * 2002-10-31 2004-08-19 Supergen, Inc., A Delaware Corporation Pharmaceutical formulations targeting specific regions of the gastrointesinal tract
US20040102201A1 (en) * 2002-11-22 2004-05-27 Levin Robert E. System and method for language translation via remote devices
CA2520522C (en) 2003-03-28 2012-05-29 Ivax Corporation Cladribine formulations for improved oral and transmucosal delivery
DK2805723T3 (da) 2004-12-22 2018-01-29 Merck Serono Sa Cladribin-regime til behandling af multipel sclerose
CA2649810A1 (en) * 2006-05-24 2007-11-29 Laboratoires Serono S.A. Cladribine regimen for treating multiple sclerosis

Also Published As

Publication number Publication date
US12171775B2 (en) 2024-12-24
PT3654989T (pt) 2024-02-28
CA3095893A1 (en) 2019-01-24
PL3654989T3 (pl) 2024-05-20
EP3654989B1 (en) 2024-01-03
WO2019016505A1 (en) 2019-01-24
US20200163986A1 (en) 2020-05-28
HUE066238T2 (hu) 2024-07-28
GB201711800D0 (en) 2017-09-06
EP4292663A3 (en) 2024-03-20
HRP20240282T1 (hr) 2024-05-10
EP3654989A1 (en) 2020-05-27
EP4292663A2 (en) 2023-12-20
LT3654989T (lt) 2024-03-25
JP7186214B2 (ja) 2022-12-08
JP2020527156A (ja) 2020-09-03
RS65246B1 (sr) 2024-03-29
SI3654989T1 (sl) 2024-06-28
DK3654989T3 (da) 2024-02-26
GB2564717A (en) 2019-01-23
US20250302858A1 (en) 2025-10-02
FI3654989T3 (fi) 2024-03-21

Similar Documents

Publication Publication Date Title
ES2655291T3 (es) Uso de cladribina para tratar neuromielitis óptica
US20250302858A1 (en) Use of cladribine for treating autoimmune neuromuscular disease
US20250189542A1 (en) Diagnostic or predictor of relapsing remitting multiple sclerosis
WO2012056344A1 (es) Uso de una composición en base a espironolactona, que presenta una acción inhibitoria de la activación de linfocitos t útil para prevenir y/o tratar esclerosis múltiple
CA3188003A1 (en) Use of btk inhibitors in the treatment of diseases
HK40106667A (en) Use of cladribine for treating autoimmune neuromuscular disease
Voinov Plasmapheresis in Treatment of Myasthenia Gravis
RU2837046C1 (ru) Применение ингибиторов btk при лечении заболеваний
HK40031112B (en) Use of cladribine for treating autoimmune neuromuscular disease
HK40031112A (en) Use of cladribine for treating autoimmune neuromuscular disease
GB2601786A (en) Use of cladribine for treating immune brain disease
AU1859399A (en) 2-halo-2'-deoxyadenosine treatment for inflammatory bowel disease